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To assess the efficacy and safety of mycophenolate mofe-
til (MMF) in patients with localized scleroderma (LoS) 
resistant or intolerant to previous treatment with metho­
trexate (MTX). A case series of patients with LoS trea-
ted with MMF. Outcome was assessed through clinical 
examination. Adverse events were documented. Seven 
patients with LoS were treated with MMF. Median age 
at MMF initiation was 15 years (range 7–74 years). 
Three patients received MMF due to MTX ineffective-
ness and 4 due to MTX intolerance. Disease remission 
was achieved in 4 patients and maintained in one pa-
tient. One patient showed a favourable response, but had 
to discontinue treatment due to elevated liver enzymes. 
The remaining patient experienced disease progression. 
MMF was shown to improve the clinical condition of pa-
tients with refractory LoS and may be a relatively safe 
alternative in patients who are intolerant to MTX. Key 
words: localized scleroderma; morphea; mycophenolate 
mofetil; methotrexate.
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Localized scleroderma (LoS), also known as morphea, 
encompasses a spectrum of sclerotic skin diseases prima-
rily affecting the dermis, but may also affect underlying 
tissues such as subcutaneous fat, fascia, muscle and 
underlying bone (1). The different subtypes of LoS may 
vary in severity and are classified into morphea en pla-
que, linear LoS, generalized LoS, deep LoS, pansclerotic 
morphea and the mixed subtype (2). Morphea en plaque 
is the most common variant in adults. Linear LoS is the 
most frequently observed subtype in children and is 
usually accompanied by fibrosis of the underlying tissues 
of the limbs and face. In severe cases the disease results 
in muscle atrophy, growth restrictions of the limbs and 
joint contractures, leading to discomfort, dysfunctional 
use and psychological distress (3–5). In LoS, treatment 
consists of topical corticosteroids, vitamin D analogues 
or calcineurin inhibitors, low-dose methotrexate (MTX), 
systemic corticosteroids and ultraviolet A1 (UVA1) pho-
totherapy (6, 7). For some patients with severe debilita-
ting deformities these treatments are not sufficient, due 
to progressive disease and/or intolerance to treatment. 
In these refractory cases of LoS, mycophenolate mofetil 
(MMF) may be beneficial. However, literature supporting 
this evidence is scarce, with only one article reporting 
beneficial results of this treatment option in LoS (8). The 
aim of this concise report is to provide more evidence 
of the efficacy and safety of MMF therapy in patients 
with severe LoS.
MATERIALS AND METHODS
A retrospective chart review was performed of patients with 
LoS treated with MMF, at the Radboud University Medical 
Centre, Nijmegen, The Netherlands. Disease subtype clas-
sification was based on the classification system proposed by 
Zulian et al. (9). The diagnosis was made by clinical inspection 
and confirmed with skin biopsies if necessary. Treatment with 
MMF was initiated when treatment with MTX as a treatment 
for LoS, in combination with systemic corticosteroid therapy, 
did not result in disease remission or stabilization, or when 
intolerance to MTX occurred. Active disease was defined as 
the presence of one of the following items: an erythematous 
border (“lilac ring”) surrounding a lesion, or disease progres-
sion (development of new lesions, expansion of existing lesions, 
expansion of sclerosis, decrease in the range of motion (RoM) 
of an affected limb, or imaging studies showing signs of disease 
activity). Inactive disease was defined as the absence of the 
above-mentioned items for disease activity. Disease remis-
sion was defined as 6 consecutive months of inactive disease. 
A favourable response to treatment with MMF was defined 
as disease remission or absence of disease recurrence during 
follow-up. All patients were evaluated by both a dermatologist 
and a rheumatologist, with extensive experience in the treatment 
of LoS in paediatric and adult patients, respectively. Extracu-
taneous manifestations (ECMs) were recorded as previously 
reported by Zulian et al. (9)
RESULTS
Patients
Clinical characteristics are described in Table I. Seven 
patients with LoS, 6 females and 1 male, were treated 
with MMF at our centre. The median age at MMF ini-
tiation was 15 years (range 7–73 years). LoS subtypes 
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included were deep (n = 2), linear (n = 1), generalized 
(n = 2) and mixed subtypes (n = 2). Two patients, both 
classified with generalized subtype of LoS, had an 
overlap diagnosis with systemic sclerosis (SSc). One of 
these patients was diagnosed with a diffuse cutaneous 
SSc (dcSSc), based on the presence of Raynaud’s 
phenomenon, sclerodactyly, positive ANA, positive 
anti-topoisomerase-I, abnormal nail-fold capillaries 
and a diffuse pattern of thickening of the skin. The 
other patient was diagnosed with a limited cutaneous 
SSc (lcSSc), based on the presence of Raynaud’s phe-
nomenon, digital ulcers, sclerodactyly, positive ANA 
and anti-centromeres and oesophageal dysmotility. In 
the 2 patients diagnosed with SSc, MMF treatment was 
initiated due to progression of the LoS lesions. The 
remaining 5 patients were solely diagnosed with LoS. 
One patient (#1) was diagnosed with mild pulmonary 
restriction at the initial presentation of LoS, which 
remained stable during the 6 years of follow-up. This 
patient also experienced a decreased RoM of the wrist 
and knee. No other ECMs, especially no arthritis, were 
reported in the patients.
Treatment
All patients were treated with systemic corticosteroids 
and MTX, with maximum doses up to 25 mg admi-
nistered orally and subcutaneously, prior to starting 
treatment with MMF (Table II). Two patients (# 6 and 
7) had a history of treatment with azathioprine. The 
patient with dcSSc had received cyclophosphamide 
because of progressive skin disease, with good response 
of dcSSc, but not of LoS. In addition, she was trea-
ted with rituximab previous to MMF initiation. Four 
patients had experienced MTX intolerance (nausea, 
abdominal discomfort, elevated liver enzymes), which 
was the incentive to start MMF therapy. In 3 patients 
MMF therapy was started because of ineffective prior 
treatment with MTX. Median duration of disease at the 
start of MMF therapy was 46 months (range 21–194 
months). Six out of 7 patients showed signs of disease 
activity at the start of MMF treatment. In the remaining 
paediatric patient, MMF was started as a treatment to 
maintain disease remission. All patients discontinued 
MTX treatment, ranging from 1 week to 3 years, prior 
to MMF initiation. Five patients (#1, 3, 4, 6 and 7) were 
treated concomitantly with prednisone treatment. Two 
of these 5 patients were already being treated with 10 
mg prednisone daily for several years prior to MMF 
initiation and no dose alterations were made during the 
treatment episode of MMF. One patient (# 3) received 
7.5 mg prednisone daily for 6 weeks at the same time as 
the MMF dose was increased. Another patient (# 1) was 
being treated with up to 30 mg prednisone daily for the 
first 6 months of MMF treatment. The remaining patient 
(# 4) received 20 mg prednisone for the first 2 months of 
MMF treatment. The starting dose of MMF ranged from 
500 to 2,000 mg daily and the maximum dose prescribed 
was 2,500 mg daily. Median duration of MMF treatment 
at data lock was 15 months (range 9–40).
Outcome: disease course 
As described in Table II, 6 patients had a favourable 
response to MMF treatment. Of the patients who 
started MMF treatment, while having active disease, 
4 patients (#1, 3, 4 and 6) achieved disease remission. 
After initial disease remission during MMF treatment, 
patient #1 had a disease recurrence, which responded 
favourably after dose increase of MMF. In addition, 
the RoM returned to normal during treatment. Patient 
#3 also experienced disease remission after dose 
increase. Patient #4 experienced disease remission 
without dose increase. One patient with generalized 
LoS (#6) experienced clinical improvement of the 
LoS, but progression of the systemic manifestations 
of SSc. Patient #7 experienced clinical improvement, 
but had to discontinue MMF treatment after 3 months 
due to elevated liver enzymes. One patient (#2) already 
had disease remission prior to starting treatment with 
MMF; therapy with MMF was started due to MTX in-
tolerance and the aim of the treatment was to maintain 
disease remission. Only one patient (#5) was reported 
to show progression of disease during 12 months of 
treatment with MMF.
Outcome: MMF discontinuation and safety
Of the 7 patients, 3 (#1, 2 and 6) were still being treated 
with MMF at the data lock. Patient #3 stopped on his 
Table I. Overview of patients’ characteristics
Pat. No./
Sex Clinical subtype Affected areas Autoimmune-serology
Follow-up 
months
1/M Deep LoS Anterior and posterior trunk, left arm and left leg 1+ ANA (homogeneous), + Anithiston 81
2/F Mixed Anterior and posterior trunk, left and right leg Not available 26
3/F Linear LoS Right leg Negative 37
4/F Mixed Head, anterior trunk, left arm and left leg Weak positive ANA (homogeneous), ENA – 40
5/F Generalized LoS and dcSSc Anterior and posterior trunk, left and right arm 3+ ANA (nucleolar), + Anti-topoisomerase I 61
6/F Generalized LoS and lcSSC Left and right leg 3+ ANA (centromeric), + Anti-Centromere 118
7/F Deep LoS Left and right leg Negative 40
LoS: localized scleroderma; MEP: morphea en plaque; ECDS: en coup de sabre; ANA: anti-nuclear antibody; ENA: extractable nuclear antigens.
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own initiative at the time of disease remission. There 
was no report of adverse events in this patient. In patient 
#4, MMF was discontinued after disease remission was 
present for one year. In patient #5, MMF was inef-
fective and treatment was therefore discontinued after 
12 months. This patient also experienced diarrhoea at 
MMF doses greater than 1,000 mg daily. Lastly, patient 
#7 developed elevated liver enzymes after 3 months of 
MMF treatment, leading to discontinuation of treatment.
DISCUSSION
The current paucity of evidence about MMF treatment 
in patients with LoS motivated us to analyse the ef-
ficacy and safety of MMF in these patients from our 
hospital. Our findings indicate that MMF may be a 
suitable alternative to MTX in patients who experience 
MTX-intolerance or insufficient disease control, consi-
dering that the majority of our patients achieved disease 
remission when using MMF. One patient with an exten-
sive history of LoS refractory to various medications 
showed disease progression under MMF treatment. 
MMF is an ester derivative of mycophenolic acid 
(MPA), which selectively and non-competitively inhibits 
an important enzyme, inosine monophosphate dehydro-
genase, required for the proliferation of lymphocytes. 
Therefore, blocking this enzyme may specifically inhibit 
multiple functions of lymphocytes. MMF was initially 
used for prevention of organ transplant rejection and, 
several years later, use of MMF for dermatological 
conditions ensued. In addition, in vitro studies have 
shown that MMF also inhibits proliferation of smooth 
muscle cells and fibroblasts, making it a potentially 
promising treatment for sclerodermatous conditions as 
well (10, 11). A previous case series described stabiliza-
tion of lung disease in patients with dcSSc treated with 
MMF (12). Furthermore, one prospective observational 
study of MMF reported a marked improvement in skin 
involvement in patients with progressive dcSSc (13). A 
review by Cappelli et al. (14) describes several obser-
vational studies with encouraging results of MMF on 
the modified Rodnan Skin Score in patients with SSc. 
SSc and LoS probably share a common pathway, given 
that the same cytokines and chemokines are activated, 
leading to increased collagen and extracellular matrix 
deposition (4). These findings further support that MMF 
could also be efficacious in patients with LoS. 
Compared with other immunosuppressant medica-
tions, including MTX, MMF has a favourable side-effect 
profile (15). Common side-effects of MMF are gastro-
intestinal symptoms, such as diarrhoea and nausea. Hae-
matological abnormalities, most frequently leucopaenia, 
and increased susceptibility to infections, such as urinary 
tract infections, are also commonly observed (11). In this 
case series, one patient developed elevated liver enzy-
mes after 3 months of treatment with MMF, and another Ta
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patient experienced diarrhoea at MMF doses exceeding 
1,000 mg daily. No other side-effects were reported.
One of the limits of the current study is that the effect 
of previous treatment, such as MTX, in LoS lasts for 
an unknown period of time. Six out of 7 patients were 
treated with MMF for at least 9 months, most likely 
dissipating an MTX effect. Another possibility is that 
the disease remission is due to the natural course of 
disease, given that an unknown percentage of lesions 
tend to slowly soften over a period of 3–5 years (4). 
However, all cases had a history of difficult-to-treat 
LoS with refractoriness to systemic treatments, which 
makes spontaneous remission less probable. It is also 
important to note that 5 out of 7 patients received conco-
mitant treatment with prednisone. Two of these patients 
were already being treated with low-dose prednisone 
for multiple years prior to MMF initiation and no dose 
alterations were made during the treatment episode of 
MMF. In the remaining 3 patients, prednisone was either 
prescribed at the initiation or during the course of MMF 
treatment, making it difficult to attribute the favourable 
therapeutic effect solely to MMF. In addition, this study 
is limited by its retrospective design and small sample 
size. Lastly, validated clinical scores, such as the LoScat 
(16, 17) or media RSS, were not routinely performed, as 
these patients were treated in daily practice care. 
Reviews of LoS treatment mention the use of MMF in 
patients with LoS intolerant or refractory to MTX (1, 18, 
19). However, to date, only one case series by Martini et 
al. (8) has described the effect of MMF in LoS patients, 
emphasizing the need for additional evidence to support 
this proposition. Martini et al. describe continuation of 
MTX treatment, concomitantly with MMF in 6 patients. 
In our study, all patients discontinued treatment with 
MTX at the start of MMF. Hence, our description of 
case series provides additional evidence for the efficacy 
and safety of MMF in patients with LoS and facilitates 
the decision to opt for MMF in LoS. However, further 
randomized controlled studies are warranted to further 
evaluate the efficacy of MMF in patients with LoS. 
In conclusion, MMF may be a safe alternative in se-
vere MTX-refractory or MTX-intolerant patients with 
LoS and may be an efficacious alternative to MTX in 
patients with severe LoS. More evidence is needed to 
compare MMF with MTX in patients with severe LoS.
The authors declare no conflicts of interest. 
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